Summary & Overview

HCPCS G6044: Cocaine or Metabolite Test

HCPCS Level II code G6044 designates laboratory testing for cocaine or its metabolite, a commonly ordered toxicology assay with implications for forensic, clinical, and substance-use treatment settings. Nationally, such testing informs care pathways, custody and legal decisions, workplace screening, and monitoring of patients in treatment programs. The code standardizes reporting for payers and providers that handle toxicology billing across clinical laboratories.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a compact overview of what G6044 represents, typical sites where the service is performed, and which major payers cover the service. The publication also outlines expected benchmarks for billing and utilization patterns, highlights relevant policy and coverage considerations that influence lab reimbursement, and summarizes clinical context for ordering cocaine metabolite testing.

This resource is intended to orient revenue cycle staff, laboratory directors, and policy analysts to the billing nomenclature and operational setting for G6044, and to provide a concise reference for payer coverage alignment and clinical use cases. Data not available in the input.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG6044HCPCS Level IItoxicologydrug screeninglaboratorycocaine metaboliteoutpatient labclinical testing

Billing Code Overview

HCPCS Level II code G6044 represents testing for cocaine or its metabolite. This billing entry captures laboratory analysis used to detect the presence of cocaine exposure.

Service type: Toxicology/drug screening laboratory service
Typical site of service: Clinical laboratory or outpatient specimen collection site

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is a 28-year-old adult presenting to an emergency department or an outpatient toxicology/toxicology clinic after potential exposure or suspected use of illicit stimulants. Indications for testing include altered mental status, suspected overdose, forensic evaluation, pre-employment or workplace testing, or monitoring of substance use disorder treatment. The clinical workflow begins with triage evaluation and clinical history; a clinician orders a targeted urine or serum toxicology screen for cocaine or its metabolite. A specimen is collected (usually urine) with chain-of-custody procedures when required. The laboratory performs an immunoassay screen followed by confirmatory testing (e.g., gas chromatography–mass spectrometry) when initial screen is positive. Results are reported to the ordering clinician and documented in the medical record. The laboratory component-only modifier TC may be appended when the technical component is billed separately from the professional component.

Coding Specifications

Modifier	Description	When to Use
`TC`	Technical component	Use when billing for the laboratory technician, equipment, and supplies only (no professional interpretation billed).
`26`	Professional component	Use when billing for the physician or laboratorian interpretation/reporting separate from the technical component.
`91`	Repeat clinical diagnostic lab test	Use when the same test is repeated on the same day to confirm prior result due to an unexpected or inconsistent result.
`59`	Distinct procedural service	Use when a separate and distinct laboratory procedure is performed concurrently that is not ordinarily billed together.
`90`	Reference (outside) laboratory	Use when the specimen is sent to an outside reference lab and that lab bills separately.
`QW`	CLIA waived test	Use when the test performed is a CLIA-waived point-of-care assay (if applicable).
`RT`	Right side	Rarely applicable to lab tests; included when laterality reporting is required by payors for a paired specimen (seldom used for toxicology).
`LT`	Left side	See `RT` note above.
`GY`	Item or service not furnished as ordered	Use when the laboratory will not provide the test and the facility notifies the payer.
`GZ`	Item or service expected to be denied as not reasonable and necessary	Use when the provider anticipates noncoverage and elects to proceed without advance notice of denial.

Taxonomy Code	Specialty	Notes
207Q00000X	Clinical Pathology	Clinical pathologists oversee toxicology testing and result interpretation.
207K00000X	Anatomic and Clinical Pathology	Physicians with combined training who manage laboratory services including toxicology.
208M00000X	Emergency Medicine	Emergency physicians commonly order cocaine metabolite testing for acute presentations.
371K00000X	Medical Toxicology	Medical toxicologists consult for complex overdose and confirmatory testing decisions.
261QM0800X	Addiction Medicine	Addiction specialists order and interpret urine drug testing for monitoring treatment adherence.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`R78.89`	Other specified abnormal findings of blood chemistry	General code for abnormal toxicology findings when a more specific code is not applicable; may be used for positive cocaine metabolite findings in some settings.
`F14.10`	Cocaine abuse, uncomplicated	Indicates cocaine use when testing confirms presence of cocaine metabolites; relevant for substance use disorder documentation.
`F14.20`	Cocaine dependence, uncomplicated	Used when chronic use and dependence are identified and corroborated by testing.
`T40.5X1A`	Poisoning by cocaine, accidental (unintentional), initial encounter	Used in acute overdose presentations where cocaine ingestion/administration is implicated and testing supports the diagnosis.
`T40.5X4A`	Poisoning by cocaine, undetermined, initial encounter	Used when intent of poisoning is unclear in acute presentations and testing confirms cocaine exposure.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80307`	Drug test(s), presumptive, any number of drug classes; qualitative, non-method specific, per day	Commonly used for point-of-care or lab-based presumptive urine screens that may detect cocaine metabolites as an initial screen.
`80305`	Drug test(s), presumptive, any number of drug classes; by immunoassay (e.g., enzyme immunoassay, enzyme-linked immunosorbent assay)	Used for immunoassay screening for cocaine metabolites prior to confirmatory testing.
`80320`	Drug confirmation, qualitative, confirmation of drug(s) using gas chromatography/mass spectrometry (GC/MS) or tandem mass spectrometry when performed; each drug class	Used for definitive confirmation of cocaine or benzoylecgonine when initial screen is positive.
`99000`	Handling and/or conveyance of specimen for transport to another lab	Used when specimens are couriered to reference laboratories for confirmatory testing (billing practices vary by payer).
`36415`	Collection of venous blood by venipuncture	Performed when serum testing for cocaine metabolites is required instead of or in addition to urine specimen collection.